Article Text

Original article
Prevalence of rare mitochondrial DNA mutations in mitochondrial disorders
  1. Sylvie Bannwarth1,2,
  2. Vincent Procaccio3,
  3. Anne Sophie Lebre4,
  4. Claude Jardel5,
  5. Annabelle Chaussenot1,2,
  6. Claire Hoarau1,2,
  7. Hassani Maoulida6,
  8. Nathanaël Charrier6,
  9. Xiaowu Gai7,
  10. Hongbo M Xie8,
  11. Marc Ferre3,
  12. Konstantina Fragaki1,2,
  13. Gaëlle Hardy9,
  14. Bénédicte Mousson de Camaret10,
  15. Sandrine Marlin11,
  16. Claire Marie Dhaenens12,
  17. Abdelhamid Slama13,
  18. Christophe Rocher14,
  19. Jean Paul Bonnefont4,
  20. Agnès Rötig4,
  21. Nadia Aoutil5,
  22. Mylène Gilleron5,
  23. Valérie Desquiret-Dumas3,
  24. Pascal Reynier3,
  25. Jennifer Ceresuela10,
  26. Laurence Jonard11,
  27. Aurore Devos12,
  28. Caroline Espil-Taris14,
  29. Delphine Martinez9,
  30. Pauline Gaignard13,
  31. Kim-Hanh Le Quan Sang4,
  32. Patrizia Amati-Bonneau3,
  33. Marni J Falk15,
  34. Catherine Florentz16,
  35. Brigitte Chabrol17,
  36. Isabelle Durand-Zaleski6,
  37. Véronique Paquis-Flucklinger1,2
  1. 1IRCAN, CNRS UMR 7284/Inserm U1081/UNS, Faculté de Médecine, Nice, France
  2. 2Service de Génétique Médicale, Hôpital Archet 2, CHU de Nice, Nice, France
  3. 3IBS Laboratoire de Génétique, CHU Angers, Angers, France
  4. 4Inserm U781 Service de Génétique, Hôpital Necker-Enfants Malades, Université Paris Descartes, Paris, France
  5. 5Biochimie Métabolique, Centre de Génétique moléculaire et chromosomique, Groupe hospitalier Pitié Salpétrière, Paris, France
  6. 6URCEco Ile de France, APHP, Hôpital de l'Hôtel Dieu, Paris, France
  7. 7Department of Molecular Pharmacology and Therapeutics, Loyola University Health Sciences Division, Maywood, USA
  8. 8Bioinformatics Core Facility The Children's Hospital of Philadelphia, Philadelphia, USA
  9. 9Laboratoire de Biochimie et Génétique moléculaire, CHU de Grenoble, La Tronche, France
  10. 10Service des Maladies Héréditaires du Métabolisme, Centre de Biologie et de Pathologie Est Groupement Hospitalier Est, CHU de Lyon, Bron, France
  11. 11Centre de Référence des surdités génétiques, APHP, Hôpital des Enfants Armand Trousseau, Paris, France
  12. 12UF Génopathies, Laboratoire de Biochimie, Centre de biologie CHRU de Lille et Université Lille Nord de France, Lille, France
  13. 13Laboratoire de Biochimie, CHU de Bicêtre, APHP, Le Kremlin Bicêtre, France
  14. 14Laboratoire de Physiopathologie Mitochondriale U688 INSERM, Université Victor Segalen Bordeaux 2, Bordeaux, France
  15. 15Divisions of Human Genetics and Pulmonary Medicine, The Children's Hospital of Philadelphia, Philadelphia, USA
  16. 16Architecture et Réactivité de l'ADN, Université Louis Pasteur de Strasbourg, CNRS, IBMC, Strasbourg, France
  17. 17Department of Neuropediatrics, Timone Hospital, Marseille Teaching Hospital, Marseille, France
  1. Correspondence to Professor V Paquis-Flucklinger, IRCAN UMR7284/INSERM U1081/UNS, School of Medicine, 28 av de Valombrose, 06107, Nice cedex 2, France; paquis{at}hermes.unice.fr

Abstract

Background Mitochondrial DNA (mtDNA) diseases are rare disorders whose prevalence is estimated around 1 in 5000. Patients are usually tested only for deletions and for common mutations of mtDNA which account for 5–40% of cases, depending on the study. However, the prevalence of rare mtDNA mutations is not known.

Methods We analysed the whole mtDNA in a cohort of 743 patients suspected of manifesting a mitochondrial disease, after excluding deletions and common mutations. Both heteroplasmic and homoplasmic variants were identified using two complementary strategies (Surveyor and MitoChip). Multiple correspondence analyses followed by hierarchical ascendant cluster process were used to explore relationships between clinical spectrum, age at onset and localisation of mutations.

Results 7.4% of deleterious mutations and 22.4% of novel putative mutations were identified. Pathogenic heteroplasmic mutations were more frequent than homoplasmic mutations (4.6% vs 2.8%). Patients carrying deleterious mutations showed symptoms before 16 years of age in 67% of cases. Early onset disease (<1 year) was significantly associated with mutations in protein coding genes (mainly in complex I) while late onset disorders (>16 years) were associated with mutations in tRNA genes. MTND5 and MTND6 genes were identified as ‘hotspots’ of mutations, with Leigh syndrome accounting for the large majority of associated phenotypes.

Conclusions Rare mitochondrial DNA mutations probably account for more than 7.4% of patients with respiratory chain deficiency. This study shows that a comprehensive analysis of mtDNA is essential, and should include young children, for an accurate diagnosis that is now accessible with the development of next generation sequencing technology.

  • Mitochondrial disease
  • Mitochondrial DNA
  • Rare mutations
  • Patient cohort

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Supplementary materials